Arcadia Biosciences, Inc. (NASDAQ:RKDA – Get Free Report) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 10,300 shares, a decline of 16.9% from the February 28th total of 12,400 shares. Based on an average trading volume of 15,000 shares, the short-interest ratio is presently 0.7 days. Currently, 0.8% of the company’s stock are short sold.
Arcadia Biosciences Price Performance
NASDAQ:RKDA traded down $0.26 during trading hours on Wednesday, hitting $2.67. 4,549 shares of the company were exchanged, compared to its average volume of 310,523. The company’s 50 day moving average price is $4.07 and its 200-day moving average price is $4.13. The stock has a market capitalization of $3.65 million, a price-to-earnings ratio of -0.62 and a beta of 0.78. Arcadia Biosciences has a 52-week low of $1.85 and a 52-week high of $10.31.
Hedge Funds Weigh In On Arcadia Biosciences
An institutional investor recently bought a new position in Arcadia Biosciences stock. Geode Capital Management LLC purchased a new stake in shares of Arcadia Biosciences, Inc. (NASDAQ:RKDA – Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 12,297 shares of the basic materials company’s stock, valued at approximately $73,000. Geode Capital Management LLC owned about 0.90% of Arcadia Biosciences as of its most recent filing with the SEC. Hedge funds and other institutional investors own 17.73% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Analysis on Arcadia Biosciences
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Featured Stories
- Five stocks we like better than Arcadia Biosciences
- How to Calculate Inflation Rate
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- The 3 Most Talked About Investments on WallStreetBets Right Now
- Trading Stocks: RSI and Why it’s Useful
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.